In a note put out today, Neuren is one of just 3 ASX-listed healthcare stocks recommended by Ord Minnett.
Their price target is $30.80. Of that, trofinetide is allocated a “modest” value of $10 with NNZ-2591 representing the remaining two thirds of the valuation.
In summary,
NEU stands out as a profitable, self-funding growth company with solid capital adequacy and returns.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
0.110(0.86%) |
Mkt cap ! $1.626B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.92 | $6.205M | 473.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1692 | $12.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.97 | 2196 | 12 |
View Market Depth
| Last trade - 15.36pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |